The “success” of Biogen’s Tecfidera (dimethyl fumarate) in the US in the third quarter of 2021, in the face of a plethora of generic versions of the former blockbuster treatment for multiple sclerosis, reflects a “broader problem,” and represents a “combination of several inefficiencies in the US system,” according to a leading US brokerage.
Biogen’s Tecfidera Resilience Reflects ‘Inefficiencies In US System’
Payment Quirk Also Means Doctors Currently ‘May Prefer Vumerity’
Analysts in Q3 pounced on a quirk in the complex US healthcare system that has provided small relief to Biogen’s much-depleted Tecfidera franchise in the US in the face of many generic rivals.
More from Generics
• By
After receiving a favorable court ruling last year, Lupin has secured its first-place spot for generic tolvaptan tablets in the US.
• By
The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.
• By
Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.
• By
As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.